Additionally, Alisertib (Aurora kinase A) and Crizotinib (ALK) have progressed to Phase I/II trials in combination with chemotherapy in neuroblastoma patients38, 39, 40 and the benefit of incorporating Crizotinib to upfront standard therapy for patients with newly diagnosed high‐risk neuroblastoma will be evaluated in an upcoming Phase III trial (NCT03126916). The gene discussed is ALK; the disease is neuroblastoma.